Pap picked up HSIL despite negative HPV
A recent social post shows a cervical Pap smear diagnosed as high‑grade squamous intraepithelial lesion even though high‑risk HPV testing was negative, reminding teams that cytology can catch lesions HPV screening misses. The case came from a patient with no prior cytology and was shared with images to underscore the point. This highlights that Pap cytology still has a role alongside HPV testing for detecting some high‑grade lesions. (x.com)
A cervical screening visit usually checks for two different things at once: a human papillomavirus test looks for the virus linked to most cervical cancers, and a Pap test looks directly at the shape of cervical cells under a microscope. The two tests answer different questions, which is why they can disagree on the same sample. (cancer.gov) The Pap test is the older tool, but it still does one job the virus test cannot do by itself: it can spot precancerous cells and cancer cells that are already there. The National Cancer Institute says Pap testing can find precancerous cervical cell changes, while the human papillomavirus test checks for high-risk virus types. (cancer.gov) High-grade squamous intraepithelial lesion is the label pathologists use when cervical cells look severely abnormal and close enough to cancer risk that doctors do not watch and wait. The Centers for Disease Control and Prevention table based on American Society for Colposcopy and Cervical Pathology guidance treats high-grade squamous intraepithelial lesion as a result that needs colposcopy or expedited treatment even when the human papillomavirus result is negative. (cdc.gov) That negative virus result surprises people because nearly all cervical cancers are tied to long-lasting human papillomavirus infection. The American Cancer Society still says “nearly all” rather than “all,” and screening guidance keeps Pap testing as an acceptable option because real patients do not always fit the neat rule. (cancer.org) There are a few ways this mismatch can happen. A lesion can be driven by a high-risk virus type not captured by a given test, the virus level in the sample can be too low to detect, or the abnormal cells can simply be easier to see on the slide than the viral signal is to measure in the tube. (cancer.gov, cancer.gov) That is why screening rules are built around risk, not a single lab line. The American College of Obstetricians and Gynecologists says the current system combines the current result with past screening history, and it specifically notes that high-grade squamous intraepithelial lesion can justify treatment without a prior biopsy in some adults because the immediate risk of severe precancer is high. (acog.org) History matters even more when someone has never had prior cervical cytology. The American College of Obstetricians and Gynecologists says “never or rarely screened” patients with high-grade squamous intraepithelial lesion and positive human papillomavirus are in the group where expedited treatment is preferred, which shows how strongly missed years of screening raises concern. (acog.org) The bigger takeaway is not that human papillomavirus testing failed. It is that cervical screening works best when clinicians remember what each tool is built to catch: the virus test is an early-warning smoke alarm, and the Pap test is the window that lets you see whether the room is already filling with smoke. (cancer.gov, cancer.org) That is also why major guidelines still leave more than one path on the table for people ages 30 to 65. The National Cancer Institute lists human papillomavirus testing every 5 years, combined human papillomavirus and Pap testing every 5 years, or Pap testing alone every 3 years as accepted screening approaches in that age range under current United States recommendations. (cancer.gov) A single case on social media does not rewrite screening policy, but it does illustrate the blind spot every screening program has to plan around. If a Pap slide shows high-grade squamous intraepithelial lesion, clinicians do not ignore it just because the human papillomavirus box says negative. (cdc.gov, acog.org)
